Type 2 immune responses are associated with less severe COVID-19 in a hospitalized cohort
Jayavelu N, Qi J, Milliren C, Ozonoff A, Liu S, Levy O, Baden L, Melamed E, McComsey G, Cairns C, Schaenman J, Shaw A, Hafler D, Corry D, Kheradmand F, Atkinson M, Brakenridge S, Higuita N, Metcalf J, Hough C, Messer W, Pulendran B, Nadeau K, Davis M, Geng L, Sesma A, Simon V, Krammer F, Bime C, Calfee C, Bosinger S, Eckalbar W, Steen H, Maecker H, Becker P, Augustine A, Holland S, Rosen L, Lee S, Vaysman T, Ozonoff A, Diray-Arce J, Chen J, Kho A, Milliren C, Hoch A, Chang A, McEnaney K, Barton B, Lentucci C, Murphy M, Saluvan M, Shaheen T, Liu S, Syphurs C, Albert M, Hayati A, Bryant R, Abraham J, Thomas S, Cooney M, Karoly M, Altman M, Jayavelu N, Presnell S, Kohr B, Jancsyk T, Arnett A, Peters B, Overton J, Vita R, Westendorf K, Overton J, Levy O, Steen H, van Zalm P, Fatou B, Smolen K, Viode A, van Haren S, Jha M, Stevenson D, Odumade O, Baden L, Mendez K, Lasky-Su J, Tong A, Rooks R, Desjardins M, Sherman A, Walsh S, Mitre X, Cauley J, Li X, Evans B, Montesano C, Licona J, Krauss J, Issa N, Chang J, Izaguirre N, Hutton S, Michelotti G, Wong K, Tebbutt S, Shannon C, Sekaly R, Fourati S, McComsey G, Harris P, Sieg S, Ribeiro S, Cairns C, Haddad E, Kutzler M, Bernui M, Cusimano G, Connors J, Woloszczuk K, Joyner D, Edwards C, Lee E, Lin E, Melnyk N, Powell D, Kim J, Goonewardene I, Simmons B, Smith C, Martens M, Croen B, Semenza N, Bell M, Furukawa S, McLin R, Tegos G, Rogowski B, Mege N, Ulring K, Schearer P, Sheidy J, Nagle C, Seyfert-Margolis V, Rouphael N, Bosinger S, Boddapati A, Tharp G, Pellegrini K, Johnson B, Panganiban B, Huerta C, Anderson E, Samaha H, Sevransky J, Bristow L, Beagle E, Cowan D, Hamilton S, Hodder T, Bechnak A, Cheng A, Mehta A, Ciric C, Spainhour C, Carter E, Scherer E, Usher J, Hellmeister K, Hussaini L, Hewitt L, Mcnair N, Ribeiro S, Wimalasena S, Fernandez-Sesma A, Simon V, Krammer F, Van Bakel H, Kim-Schulze S, Reiche A, Qi J, Lee B, Carreño J, Singh G, Raskin A, Tcheou J, Khalil Z, van de Guchte A, Farrugia K, Khan Z, Kelly G, Srivastava K, Eaker L, Bermúdez-González M, Mulder L, Beach K, Saksena M, Altman D, Kojic E, Sominsky L, Azad A, Bielak D, Kawabata H, Yellin T, Fried M, Sullivan L, Morris S, Kleiner G, Stadlbauer D, Dutta J, Xie H, Patel M, Nie K, Rahman A, Messer W, Hough C, Siegel S, Sullivan P, Lu Z, Brunton A, Strand M, Lyski Z, Coulter F, Micheleti C, Maecker H, Pulendran B, Nadeau K, Rosenberg-Hasson Y, Leipold M, Sigal N, Rogers A, Fernandes A, Manohar M, Do E, Chang I, Lee A, Blish C, Din H, Roque J, Geng L, Artandi M, Davis M, Ahuja N, Yang S, Chinthrajah S, Hagan T, Reed E, Schaenman J, Salehi-Rad R, Rivera A, Pickering H, Sen S, Elashoff D, Ward D, Brook J, Sanchez E, Llamas M, Perdomo C, Magyar C, Fulcher J, Erle D, Calfee C, Hendrickson C, Kangelaris K, Nguyen V, Lee D, Chak S, Ghale R, Gonzalez A, Jauregui A, Leroux C, Altamirano L, Rashid A, Willmore A, Woodruff P, Krummel M, Carrillo S, Ward A, Langelier C, Patel R, Wilson M, Dandekar R, Alvarenga B, Rajan J, Eckalbar W, Schroeder A, Fragiadakis G, Tsitsiklis A, Mick E, Guerrero Y, Love C, Maliskova L, Adkisson M, Leligdowicz A, Beagle A, Rao A, Sigman A, Samad B, Curiel C, Shaw C, Tietje-Ulrich G, Milush J, Singer J, Vasquez J, Tang K, Betancourt L, Santhosh L, Pierce L, Paz M, Matthay M, Thakur N, Rodriguez N, Sutter N, Jones N, Sinha P, Prasad P, Lota R, Rashid S, Asthana S, Bhide S, Lea T, Abe-Jones Y, Hafler D, Montgomery R, Shaw A, Kleinstein S, Gygi J, Pawar S, Konstorum A, Chen E, Cotsapas C, Wang X, Xu L, Dela Cruz C, Iwasaki A, Mohanty S, Nelson A, Zhao Y, Farhadian S, Asashima H, Chaudhary O, Coppi A, Fournier J, Muenker M, Nelson A, Raddassi K, Rainone M, Ruff W, Salahuddin S, Shulz W, Vijayakumar P, Wang H, Wunder E, Young H, Ko A, Wang X, Duchen D, Esserman D, Guan L, Brito A, Rothman J, Grubaugh N, Corry D, Kheradmand F, Song L, Nelson E, Metcalf J, Higuita N, Sinko L, Booth J, Drevets D, Brown B, Kraft M, Bime C, Mosier J, Erickson H, Schunk R, Kimura H, Conway M, Francisco D, Molzahn A, Wilson C, Schunk R, Hughes T, Sierra B, Atkinson M, Brakenridge S, Ungaro R, Manning B, Moldawer L, Oberhaus J, Guirgis F, Borresen B, Anderson M, Ehrlich L, Melamed E, Maguire C, Wylie D, Rousseau J, Hurley K, Geltman J, Siles N, Rogers J, Augustine A, Diray-Arce J, Haddad E, Sekaly R, Kraft M, Woodruff P, Erle D, Ehrlich L, Montgomery R, Becker P, Altman M, Fourati S. Type 2 immune responses are associated with less severe COVID-19 in a hospitalized cohort. Journal Of Allergy And Clinical Immunology Global 2025, 4: 100515. PMID: 40709330, PMCID: PMC12284355, DOI: 10.1016/j.jacig.2025.100515.Peer-Reviewed Original ResearchT2 immune responseClinical outcomesVirus loadImmune responseSARS-CoV-2Primary siteSusceptibility to respiratory viral infectionsType 2 immune responsesAntibody titersCellular markersPrimary site of infectionSeverity of respiratory illnessRespiratory viral infectionsIL-13 levelsDegree of respiratory supportAssociated with less severe COVID-19Site of infectionLow virus loadSevere COVID-19Effects of SARS-CoV-2Severe coronavirus diseaseDiagnosis of asthmaRespiratory supportCoronavirus severe acute respiratory syndrome coronavirus 2Blood cytometry
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply